UK MHRA Relies On Remote Drug GMP Inspections As COVID-19 Pandemic Grounds Inspectors
Experience from previous viral outbreaks has allowed the UK agency to move quickly; long-term focus is on hybrid inspection approach.
You may also be interested in...
Invalidated OOS results are ‘red flags’ during FDA inspections and ‘denying, delaying, limiting or refusing’ a drug inspection proposed by the agency could have serious consequence, participants at a recent webinar on best practices for responding to Form 483s and warnings letters heard.
Four months after suspending all non-essential on-site inspections because of the COVID-19 pandemic, the UK medicines regulator is busy finalizing the practical arrangements needed to resume these safely at local sites.
More news from across the sector, including Novartis's non-profit pledge on medicines and Zydus Cadila commencing Phase I vaccine trial.